Next-generation cDNA screening for oncogene and resistance phenotypes

Nobuaki Shindoh1, Akinori Yoda, Yuka Yoda

  • 1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America.

Plos One
|November 13, 2012
PubMed
Summary

This study presents a new platform for functional screening of genetic alterations in cancer. It efficiently identifies DNA and RNA changes driving cancer growth and drug resistance using next-generation sequencing.